

OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")

First order with well-known Weight Management Company

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces it has received a first order from a well-known weight management company (the "Distributor"). The order follows on from an agreement announced on 20 August 2025. The low six-figure first order includes the supply of a range of private label SlimBiome® finished products (gummies, bars, drinks) and a WellBiome® product planned for delivery and launch in Europe under the Distributor's own brand in H1 2026. This is consistent with the Company's strategy of providing more finished product either via ecommerce or, as in this case, private label products to customers.

The order reflects the interest in bringing ingredients with human studies which show appetite reduction similar to the anti-obesity drugs to traditional weight management brands, and new brands looking to enter the fast evolving 'natural alternative to GLP1 market', which is redefining the weight management market. This market is estimated to be worth 1.2 billion in 2024 and is projected to reach 4.8 billion by 2033, growing at a compound annual growth rate of 16.7% (Market Intelo, 2024).

This follows on from the launch of SlimBiome with a number of large partners and well-known brands internationally including:-

- I. Hydroxycut, a brand which describes itself as the No. 1 selling weight loss supplement brand in the United States of America ("USA"), which is sold online and via major retail outlets including Walmart across the USA.
- II. LightLife, a new brand from Dr Morepen which was launched online in December 2024 and is now expanding into retail across India and looking to extend their product range.
- III. The launch of SlimBiome in Holland and Barrett's SlimExpert range. We anticipate new positioning of products in 2026 reflecting the evolution of the weight management market.
- IV. The inclusion of SlimBiome as LeanBiome in leading sports brands like Muscletech and Myprotein.

Stephen O'Hara, CEO of OptiBiotix Health plc said: *"We are pleased to announce this large first order with a well-known European weight management company. The order reflects the growing interest in bringing ingredients with human studies demonstrating appetite reduction, similar to the anti-obesity drugs, to brands looking to enter this fast growing 'natural alternative to GLP1 market'.*

"This is another example of the Company launching products with well-known brands in international markets which helps build the SlimBiome brand and, if successful individually and collectively, have the potential to make a significant contribution to future sales growth and shareholder value."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

Caim Financial Advisers LLP (NOMAD and Broker)
Liam Murray / Ludovico Lazzaretti / James Western

Tel: 020 7213 0880

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF) OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFFTLVLRLE